eMedicine Specialties > Infectious Diseases > Parasitic Infections

Trichomoniasis

Author: Darvin Scott Smith, MD, MSc, DTM&H,, Adjunct Assistant Professor, Department of Microbiology and Immunology, Stanford University; Chief of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, Kaiser Redwood City Hospital
Coauthor(s): Natalia Ramos,, Stanford University, Keck School of Medicine of the University of Southern California
Contributor Information and Disclosures

Updated: Aug 20, 2008

Introduction

Background

Trichomoniasis is a sexually transmitted infection caused by the protozoa Trichomonas vaginalis. It is one of the most common sexually transmitted diseases in the United States.1 Women with trichomoniasis may experience various symptoms, including a yellow-green vaginal discharge and vulvar irritation, or they may be asymptomatic. Men with trichomoniasis are frequently asymptomatic.2

The high incidence of trichomoniasis worldwide, its contribution to poor health outcomes, and its co-infection with other sexually transmitted infections make trichomoniasis a compelling public health concern. Notably, T vaginalis infection is believed to increase the risk of HIV transmission.1 Trichomoniasis is also associated with adverse pregnancy outcomes, infertility, postoperative infections, and cervical neoplasia.3

Pathophysiology

T vaginalis is approximately the size of a white blood cell (about 10 μm in diameter), although its size may vary with physical conditions. Its flagellum allows it to move around vaginal and urethral tissues. T vaginalis directly damages the epithelium, leading to microulcerations of inhabited tissues, increasing the risk of HIV transmission.1

Symptoms of trichomoniasis typically occur after an incubation period of 4-28 days. In women, T vaginalis is isolated from the vagina, cervix, urethra, bladder, and Bartholin and Skene glands. In men, the organism is found in the anterior urethra, external genitalia, prostate, epididymis, and semen.

Frequency

United States

Approximately 8 million new cases of trichomoniasis occur annually.4 The prevalence of T vaginalis infection at clinics that treat STDs varies from 15-54%.5 In men, trichomoniasis accounts for 10-21% of urethritis cases not attributable to gonorrheal or chlamydial infection.5

International

Worldwide, the annual incidence of trichomoniasis is about 170 million cases.6 The incidence of trichomoniasis in Europe is similar to that in the United States. In Africa, the prevalence of trichomoniasis may be much higher.

Mortality/Morbidity

T vaginalis infection is highly associated with the presence of other sexually transmitted infections, including gonorrhea, chlamydia, and HIV. Persons with trichomoniasis are twice as likely to develop HIV infection as the general population.7 Two explanations exist for the association between T vaginalis and HIV: (1) Disruption of the epithelial monolayer leads to increased passage of the HIV virus; (2) T vaginalis induces immune activation, specifically lymphocyte activation and replication and cytokine production, leading to increased viral replication in HIV-infected cells.
 
Pregnant women with T vaginalis infection are more likely than uninfected women to deliver preterm or to have other adverse pregnancy outcomes, including low birth weight, premature rupture of membranes, and intrauterine infection.1 However, whether trichomoniasis causes the adverse outcome is unclear.1 T vaginalis infection may also increase the transmission of HIV owing to disruption of the vaginal mucosa. Respiratory or genital infection in the newborn should also be considered.2

One study reported a higher risk of pelvic inflammatory disease in women with trichomoniasis.8 Other studies have reported a 1.9-fold risk of tubal infertility in women with trichomoniasis.9 Trichomoniasis may also play a role in cervical neoplasia and postoperative infections.3

In men, complications of untreated trichomoniasis include prostatitis, epididymitis, urethral stricture disease, and infertility. Infertility may result from a decreased sperm motility and viability.3

See the Clinical section for presenting symptoms and signs.

Sex

Symptomatic trichomoniasis is more common in women than in men. Trichomoniasis infection in men is less clinically apparent.

Age

Trichomoniasis is a sexually transmitted infection. As such, it is typically found in sexually active adolescents and adults.

Clinical

History

Women

Trichomoniasis symptoms in women range from none to severe pelvic inflammatory disease. Women with trichomoniasis frequently report a frothy yellowish-green vaginal discharge, abnormal vaginal odor, vulvovaginal itching and soreness, dyspareunia (pain during sexual intercourse), and dysuria (pain during urination). However, many infected women experience no symptoms.

Cervicitis due to trichomoniasis is characterized by 2 major signs—purulent discharge in the endocervical canal and easily induced endocervical bleeding.2 However, it may also be asymptomatic.

T vaginalis infection is one of the top 3 causes of vaginitis.2 Vaginitis is usually characterized by vaginal discharge, which may be accompanied by vulvar itching, irritation, and odor. The two other most common causes of vaginal discharge are anaerobic bacterial overgrowth of normal flora and candidiasis (infection with Candida albicans).2

Men

Trichomoniasis symptoms in men range from none to urethritis complicated by prostatitis. Nongonococcal nonchlamydial urethritis is the most common symptom reported by men with trichomoniasis. Symptoms of urethritis include discharge, dysuria, and urethral pruritus.2 The discharge may be purulent to mucoid in character. Most symptomatic infections are intermittent and self-limiting. Complications of untreated trichomoniasis include prostatitis, epididymitis, urethral stricture disease, and infertility.

Physical

Women

  • Purulent or homogenous vaginal discharge and vulvar or vaginal erythema are common.
  • Colpitis macularis, or strawberry cervix, describes a diffuse or patchy macular erythematous lesion of the cervix. This is a specific sign for trichomoniasis but is visible in only 1-2% of cases without the aid of colposcopy. With colposcopy, colpitis macularis is detected in up to 45% of cases.
  • Lower-abdominal tenderness may be present; however, this is described in fewer than 10% of patients. If this occurs, coexisting salpingitis or an intra-abdominal pathology is possible.
  • Coexisting Neisseria gonorrhea infection, candidiasis, and bacterial vaginosis are common and may produce a mixed clinical picture.

Men

  • The findings of trichomoniasis in men on physical examination are generally unremarkable unless the infection is complicated. It may be associated with local inflammatory states, including balanitis and balanoposthitis.
  • Physical findings of epididymitis and prostatitis may also occur.

Causes

See Pathophysiology.

More on Trichomoniasis

Overview: Trichomoniasis
Differential Diagnoses & Workup: Trichomoniasis
Treatment & Medication: Trichomoniasis
Follow-up: Trichomoniasis
Multimedia: Trichomoniasis
References
Further Reading

References

  1. Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;CD000218. [Medline].

  2. Centers for Disease Control and Prevention (CDC), Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006;55:1-94. [Medline].

  3. Soper D. Trichomoniasis: under control or undercontrolled?. Am J Obstet Gynecol. Jan 2004;190(1):281-90. [Medline].

  4. Gerbase AC, Rowley JT, Mertens TE. Global epidemiology of sexually transmitted diseases. Lancet. 1998;351 Suppl 3:2-4. [Medline].

  5. Sobel JD. What's new in bacterial vaginosis and trichomoniasis?. Infect Dis Clin North Am. Jun 2005;19(2):387-406. [Medline].

  6. Patel SR, Wiese W, Patel SC, Ohl C, Byrd JC, Estrada CA. Systematic review of diagnostic tests for vaginal trichomoniasis. Infect Dis Obstet Gynecol. 2000;8(5-6):248-57. [Medline].

  7. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. Jan 1993;7(1):95-102. [Medline].

  8. Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. Feb 15 2002;34(4):519-22. [Medline].

  9. Grodstein F, Goldman MB, Ryan L, et al. Relation of female infertility to consumption of caffeinated beverages. Am J Epidemiol. Jun 15 1993;137(12):1353-60. [Medline].

  10. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol. May 2006;107(5):1195-1206. [Medline].

  11. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. Feb 1995;172(2 Pt 1):525-9. [Medline].

  12. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. Jul 2005;73(7):4155-60. [Medline][Full Text].

  13. Nanda N, Michel RG, Kurdgelashvili G, et al. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. Feb 2006;4(1):125-35. [Medline].

Further Reading

ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol. May 2006;107(5):1195-1206.
 
Abramowicz M (ed.). Drugs for Parasitic Infections. The Medical Letter. Aug 2004.
 
Burtin P, Taddio A, Ariburnu O. Safety of metronidazole in pregnancy: a meta-analysis. ALYSIS. Feb 1995;172(2 Pt 1):525-9. 
 
Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. Jul 2005;73(7):4155-60. [Full Text].
 
Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. Feb 2006;4(1):125-35.

Keywords

trichomoniasis, vaginal trichomoniasis, trichomonads, nongonococcal nonchlamydial urethritis, prostatitis, epididymitis, urethral stricture disease, pelvic inflammatory disease, colpitis macularis, vaginal discharge, vaginitis, cervicitis, dyspareunia, dysuria

Contributor Information and Disclosures

Author

Darvin Scott Smith, MD, MSc, DTM&H,, Adjunct Assistant Professor, Department of Microbiology and Immunology, Stanford University; Chief of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, Kaiser Redwood City Hospital
Darvin Scott Smith, MD, MSc, DTM&H, is a member of the following medical societies: American Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and International Society of Travel Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Natalia Ramos,, Stanford University, Keck School of Medicine of the University of Southern California
Natalia Ramos, is a member of the following medical societies: American Medical Student Association/Foundation and American Medical Women's Association
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey M Zaks, MD, Clinical Associate Professor of Medicine, Wayne State University School of Medicine; Vice President, Medical Affairs, Chief Medical Officer, Department of Internal Medicine, Providence Hospital
Jeffrey M Zaks, MD is a member of the following medical societies: American College of Cardiology, American College of Healthcare Executives, American College of Physician Executives, and American Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance
John L Brusch, MD, FACP is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.